Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.49 |
| ▸ | ACP1 | P24666 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.45 |
| ▸ | PTPRF | P10586 | 2/20 | 0.45 |
| ▸ | PTPRB | P23467 | 2/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7554112 | 0.85 | ENPP2 (0.54) | ENPP2PTPN1ACP1PTPN2PTPRF | |
| SCHEMBL5462282 | 0.78 | PTPN1 (0.66) | ENPP2PTPN1ACP1HPGDNPSR1 | |
| SCHEMBL5462289 | 0.78 | PTPN1 (0.66) | ENPP2PTPN1ACP1HPGDNPSR1 | |
| SCHEMBL7559145 | 0.78 | HPGD (0.42) | ENPP2PTPN1HPGDNPSR1HTT | |
| SCHEMBL5457203 | 0.76 | ENPP2 (0.72) | ENPP2PTPN1ACP1HPGDNPSR1 | |
| SCHEMBL5457201 | 0.76 | ENPP2 (0.72) | ENPP2PTPN1ACP1HPGDNPSR1 | |
| SCHEMBL5462864 | 0.75 | MEN1 (0.62) | ENPP2PTPN1ACP1PTPN2PTPRF | |
| SCHEMBL5462867 | 0.75 | MEN1 (0.62) | ENPP2PTPN1ACP1PTPN2PTPRF | |
| SCHEMBL7556464 | 0.70 | MEN1 (0.56) | PTPN1HPGDAKR1B1HTTMEN1 | |
| SCHEMBL7556460 | 0.70 | MEN1 (0.56) | PTPN1HPGDAKR1B1HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1109808-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002394-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | ENPP2 2363/4885PTPN1 3030/4885ACP1 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.